Innova Captab delivered impressive financial results for Q4FY26, with consolidated net profit rising 41% year-on-year to ₹403.49 crore. The company's revenue from operations for the quarter stood at ₹4,478.02 million, representing a significant increase from ₹3,147.41 million in Q4FY25. As per the latest financial results, earnings per share improved to ₹7.05 compared to ₹4.99 in the corresponding quarter of the previous year, reflecting strong operational performance.
For the full fiscal year ended March 31, 2026, Innova Captab's consolidated revenue reached ₹16,300.18 million, marking substantial growth from ₹12,436.76 million in FY25. Net profit for the year was reported at ₹1,431.83 million, up from ₹1,272.51 million in the prior year. The company's strong financial performance was supported by improved operational efficiency and strategic business decisions throughout the fiscal year.
The board of Innova Captab approved a significant capacity expansion at its existing manufacturing facility during a meeting held on 21 August 2026. The company has decided to proceed with a brownfield expansion of its Baddi manufacturing facility, marking a strategic move to enhance production capabilities. The expansion will involve the addition of 2 oral solid dosage production lines at the Baddi facility, with the total investment required for this capacity enhancement being ₹45 crore.
The current Baddi facility operates at approximately 85% to 90% capacity utilization, highlighting the urgent need for expansion. The company plans to fund this expansion through a combination of internal accruals and bank credit facilities, demonstrating its commitment to organic growth and financial discipline. This brownfield expansion represents Innova Captab's commitment to strengthening its manufacturing capabilities in the pharmaceutical sector, with the investment specifically focusing on oral solid dosage production lines to support long-term growth strategies.
The company revised its Q4FY26 and FY26 financial results following the identification of inadvertent accounting errors. The revisions primarily involved the retrospective correction of deferred tax liabilities related to a historical business combination and the recognition of a deferred tax asset under Section 80JJAA of the Income Tax Act. Additionally, Innova Captab reclassified ₹185.08 million in supplier finance arrangements from trade payables to other financial liabilities. The revision of the deferred tax liability related to the acquisition of Sharon Bio-Medicine Limited had a material impact on equity, with total assets reduced by ₹105.37 million as of April 1, 2024. Statutory auditors B S R & Co. LLP issued an unmodified opinion on the revised standalone and consolidated financial results, ensuring compliance with regulatory requirements.
